Pistoia Alliance Conference 2026: Leveraging Modern Data Capabilities to Increase the Efficiency of Pharmaceutical R&D
The stakes are high. According to an Accenture report cited during the Strategic Portfolio Review, 83 percent of life sciences executives acknowledge they will miss their growth targets without significant digital and data-driven transformation. A speaker representing Parexel drove home the necessity of this transformation by illustrating the logarithmic decline in FDA-approved drugs relative to the R&D spending. Drug discovery remains a complex, inefficient process, full of opportunities for improvement. The challenge now is to implement the foundational data, knowledge, and governance changes needed to revitalize the pipeline.
Until organizations commit to solving the culture and change readiness challenge with the same rigor they apply to data infrastructure and advanced analytics, the promise of R&D transformation will remain limited. The community consensus is clear: the future of drug discovery depends on rigorous data governance and making change management part of the status quo.
Read More
